

Author disclosures are available with the text of this letter at www.atsjournals.org.

Arunava Ghosh, Ph.D.
Saira Ahmad, Ph.D.
Raymond D. Coakley, M.D.
M. Flori Sassano, Ph.D.
Neil E. Alexis, Ph.D.
Robert Tarran, Ph.D.*
*University of North Carolina at Chapel Hill
Chapel Hill, North Carolina*

ORCID ID: 0000-0002-8598-2642 (R.T.).

*Corresponding author (e-mail: robert_tarran@med.unc.edu).

References

1. Reagan-Steiner S, Gary J, Matkovic E, Ritter JM, Shieh WJ, Martines RB, *et al.*; Lung Injury Response Pathology Working Group. Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series. *Lancet Respir Med* 2020;8: 1219–1232.
2. Kligerman S, Raptis C, Larsen B, Henry TS, Caporale A, Tazelaar H, *et al.* Radiologic, pathologic, clinical, and physiologic findings of electronic cigarette or vaping product use-associated lung injury (EVALI): evolving knowledge and remaining questions. *Radiology* 2020;294: 491–505.
3. Guerrini V, Panettieri RA Jr, Gennaro ML. Lipid-laden macrophages as biomarkers of vaping-associated lung injury. *Lancet Respir Med* 2020; 8:e6.
4. Trapnell BC, Whitsett JA. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. *Annu Rev Physiol* 2002;64:775–802.
5. Balmes JR. Vaping-induced acute lung injury: an epidemic that could have been prevented. *Am J Respir Crit Care Med* 2019;200: 1342–1344.
6. Blount BC, Karwowski MP, Shields PG, Morel-Espinosa M, Valentin-Blasini L, Gardner M, *et al.*; Lung Injury Response Laboratory Working Group. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. *N Engl J Med* 2020;382:697–705.
7. McCarthy C, Keane MP, Fabre A. Lipid-laden macrophages are not diagnostic of pulmonary alveolar proteinosis syndrome and can indicate lung injury. *Am J Respir Crit Care Med* 2020;202:1197–1198.
8. Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, *et al.* Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. *J Clin Invest* 2019;129:4290–4304.
9. Ghosh A, Keating J, Coakley R, Ehrmann B, Alexis N, Tarran R. Vaping associated alterations in the lung lipidome [abstract]. *Am J Respir Crit Care Med* 2020;201:A7682.
10. Ghosh A, Keating JE, Coakley RD, Ehrmann BM, Alexis NE, Tarran R. Vaping associated alterations in the lung lipidome [abstract]. New Orleans, LA: Society for Research on Nicotine and Tobacco; 2020.
11. Ghosh A, Coakley RD, Ghio AJ, Muhlebach MS, Esther CR Jr, Alexis NE, *et al.* Chronic E-cigarette use increases neutrophil elastase and matrix metalloprotease levels in the lung. *Am J Respir Crit Care Med* 2019;200:1392–1401.
12. Khubchandani KR, Snyder JM. Surfactant protein A (SP-A): the alveolus and beyond. *FASEB J* 2001;15:59–69.
13. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, *et al.* Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. *J Clin Invest* 2003; 111:1589–1602.
14. Awasthi S. Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. *Recent Pat Antiinfect Drug Discov* 2010; 5:115–123.
15. Shields PG, Song MA, Freudenheim JL, Brasky TM, McElroy JP, Reisinger SA, *et al.* Lipid laden macrophages and electronic cigarettes in healthy adults. *EBioMedicine* 2020;60:102982.
16. Eissenberg T, Maziak W. Are electronic cigarette users at risk for lipid-mediated lung injury? *Am J Respir Crit Care Med* 2020;201: 1012–1013.

Copyright © 2021 by the American Thoracic Society



Spirometric Classifications of Chronic Obstructive Pulmonary Disease Severity as Predictive Markers for Clinical Outcomes: The HUNT Study

The classification of chronic obstructive pulmonary disease (COPD) severity is important in guiding therapy and prognosis (1). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has recommended GOLD grades (1) based on post-bronchodilator percentage-predicted FEV₁ (ppFEV₁), which is widely used in respiratory medicine. However, ppFEV₁ has been criticized because of its susceptibility to physiological variation (2–4). Studies have recommended alternative expressions of FEV₁ that could be used for the classification of COPD severity (2, 3, 5–9). For the first time, we have compared the predictive abilities of a broad range of FEV₁ expressions for cause-specific mortality and hospitalization.

Some of the results of these studies have been previously reported in the form of a preprint (<https://doi.org/10.1101/2020.11.03.20221432>).

Methods

This study included people aged ≥40 years who participated in the HUNT2 Study (Trøndelag Health Study 2) during 1995–1997 ($n = 44,384$; 75.2% participation). A 5% random sample ($n = 2,300$) and people reporting asthma-related symptoms, diagnosis, or use of medication ($n = 7,123$) were invited to perform spirometry (10). For the analysis, we included 890 people

§This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>).

Supported by ExtraStiftelsen Helse og Rehabilitering and Landsforeningen for hjerte-og-lungesyke (the Norwegian Extra Foundation for Health and Rehabilitation and the Norwegian Heart and Lung Patient Organization) (project number 2016/FO79031) and the liaison committee of the Central Norway Regional Health Authority Norwegian University of Science and Technology (NTNU). B.M.B. works in a research unit funded by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU; The Liaison Committee for Education, Research and Innovation in Central Norway; the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU; and the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/1). D.C. works in a unit funded by the UK Medical Research Council (MC_UU_00011/1) and the University of Bristol.

Author Contributions: L.B., L.L., A.L., and B.M.B. conceived and designed the study. L.B. analyzed the data. L.B. wrote the first draft of the manuscript. All authors interpreted the results and revised and approved the manuscript for submission. L.B. and B.M.B. are accountable for the accuracy and integrity of all parts of the work. As project leader for the Lung Study in HUNT2, A.L. was responsible for planning, data collection, and quality assurance of data in the lung study.

Originally Published in Press as DOI: 10.1164/rccm.202011-4174LE on December 17, 2020

with COPD who met both the fixed ratio (post-bronchodilator $FEV_1/FVC < 0.70$) and lower limit of normal criteria and had respiratory symptoms (daily cough in periods, cough with phlegm, wheezing, or dyspnea) and/or self-reported doctor-diagnosed COPD (1, 11).

Post-bronchodilator spirometry was performed 30 minutes after inhalation of 1 mg of terbutaline according to the 1994 American Thoracic Society guidelines (12, 13). Quality assurance of spirometric measurements is described in detail elsewhere (13, 14).

We defined expressions of FEV_1 such as $ppFEV_1$, FEV_1 z-score, $FEV_1 \cdot Ht^{-2}$, $FEV_1 \cdot Ht^{-3}$, and FEV_1Q (described in detail in Reference 15) as suggested by the previous studies (1–3, 5, 6, 8, 9, 16). The Global Lung Function Initiative 2012 reference equation was used to calculate $ppFEV_1$, $ppFVC$, FEV_1 z-scores, and FVC z-scores (11, 13). FEV_1 was standardized by the square of height in meters to calculate $FEV_1 \cdot Ht^{-2}$ (6, 9) and by the cube of height in meters to calculate $FEV_1 \cdot Ht^{-3}$ (5, 8). FEV_1 was standardized by sex-specific lowest percentile (0.5 L for men and 0.4 L for women) of FEV_1 distribution among patients to calculate FEV_1Q , as suggested by Miller and Pederson in a large European population consisting of three cohorts (5).

Follow-up and outcomes. The study outcomes were all-cause mortality, respiratory mortality, cardiovascular mortality, the first unplanned COPD hospitalization, and the first unplanned pneumonia hospitalization. Participants were followed for 5 years, and right-censoring events were emigration ($n = 3$) or end of follow-up. Cause-specific mortality and hospitalizations were identified using International Classification of Diseases codes from medical records and are described in detail elsewhere (15).

Statistical analysis. Cumulative incidence curves for all-cause mortality were constructed through Kaplan-Meier estimates, and log-rank tests were used to test differences.

A regression tree method (17) that accounts for time and multiple outcomes was applied to obtain optimal cutoffs of FEV_1Q (2.8, 4.1, and 5.2), termed FEV_1Q grades.

We applied incident/dynamic time-dependent areas under the receiver operating characteristic curves (AUCs) that account for time to compare the predictive abilities of FEV_1 expressions and their respective methods of classification of COPD severity to predict clinical outcomes (18–21). For cause-specific mortality and hospitalization, AUCs accounting for competing risks were calculated (20). We used crude models to compare AUCs because the clinical decision does not explicitly take into account other factors (5). We used 10,000 bootstrap iterations to calculate the 95% confidence interval for AUCs (22). A general bootstrap algorithm (23) was applied to compare the AUCs.

Statistical analysis was performed using R 3.6.1 software (<http://www.r-project.org>).

Ethics. Ethical approval was obtained from the Regional Committees for Medical and Health Research Ethics (2015/1461/REK midt). All participants gave informed written consent.

Results

During the follow-up period, 146, 30, and 56 subjects died because of all causes, respiratory diseases, and cardiovascular diseases, respectively, and 172 and 96 were hospitalized because

of COPD and pneumonia, respectively. At baseline, the average age of participants was 63.8 years, 6 of 10 participants were men, and more than half (53.3%) of participants were current smokers (15). A trend for increasing cumulative incidence of all-cause mortality with worsening categories of classifications of COPD severity was observed (Figure 1).

When using FEV_1 expressions as continuous measures, the AUCs for all-cause mortality were 64.5 for $ppFEV_1$, 58.8 for FEV_1 z-score, 68.9 for $FEV_1 \cdot Ht^{-2}$, 69.3 for $FEV_1 \cdot Ht^{-3}$, and 70.2 for FEV_1Q (P value for AUCs between $ppFEV_1$ and $FEV_1Q < 0.001$). Similar patterns of AUCs were observed for cause-specific mortality and hospitalization, except for respiratory mortality ($P = 0.062$) (Figure 2).

The FEV_1Q grades had higher AUCs compared with GOLD grades for predicting all-cause mortality ($P < 0.001$), cardiovascular mortality ($P = 0.005$), COPD hospitalization ($P < 0.001$), and pneumonia hospitalization ($P < 0.001$) but not for respiratory mortality ($P = 0.464$) (Figure 2). Similar patterns of AUCs were observed when using FEV_1 expressions as $ppFEV_1$ quartiles and FEV_1Q quartiles, except for respiratory mortality ($P = 0.848$) and cardiovascular mortality ($P = 0.381$) (Figure 2).

Discussion

In this population-based study, we found that among all FEV_1 expressions, FEV_1Q was the best predictor of clinical outcomes studied, followed by $FEV_1 \cdot Ht^{-2}$ or $FEV_1 \cdot Ht^{-3}$, across 5 years of follow-up. For respiratory mortality, the smaller sample size gives imprecise estimates, resulting in a marginally similar predictive ability for FEV_1Q and $ppFEV_1$.

FEV_1 is a continuous variable, the expression of FEV_1 is used for indicating lung function impairments in respiratory medicine, and $ppFEV_1$ is most commonly used for this purpose (1). The GOLD grades based on $ppFEV_1$ have been widely used for clinical purposes in classifying COPD severity (1). However, they have been criticized because of their susceptibility to physiological variation and poor prediction ability (2–4, 6). The FEV_1 z-score avoids this bias due to physiological variation (2, 3). In addition, $ppFEV_1$ and FEV_1 z-scores are based on reference values and depend on the choice of reference equation; therefore, performance might vary with reference values (11, 13, 24, 25). Miller and colleagues (5–7) found that FEV_1 expressions such as $FEV_1 \cdot Ht^{-2}$, $FEV_1 \cdot Ht^{-3}$, and FEV_1Q , which are independent of reference equations, were better correlated with mortality than those that are dependent on reference equations. In addition, Miller and Pedersen (5) found that FEV_1Q predicted mortality better than other FEV_1 expressions. Extending this knowledge, our study supports FEV_1Q as a stronger predictor than other FEV_1 expressions in predicting multiple clinical outcomes. This indicates that the severity in people with COPD appears to be better related to how far the FEV_1 of that person is from the “bottom line” rather than how far it is from a “predicted value.”

The predictive ability of a classification of COPD severity based on a FEV_1 expression largely depends on the choice of cutoffs. For example, the GOLD grades and $ppFEV_1$ quartiles had different predictive abilities in our study. Huang and colleagues (4) observed similar results. Therefore, the optimal cutoffs of FEV_1 expressions for classification of COPD severity were investigated in this study, and we found that cutoffs for FEV_1Q (2.8, 4.1, and 5.2; FEV_1Q grades) were generally best in predicting clinical outcomes. The optimal




Figure 1. Cumulative incidence curves of classifications of chronic obstructive pulmonary disease (COPD) severity for all-cause mortality among participants with COPD aged ≥ 40 years in the HUNT2 Study (Trøndelag Health Study 2) (1995–1997) followed for 5 years. $FEV_1 \cdot Ht^{-2} = FEV_1$ standardized by square of height in meters; $FEV_1 \cdot Ht^{-3} = FEV_1$ standardized by cube of height in meters; $FEV_1Q = FEV_1$ standardized by sex-specific lowest percentile (0.5 L for men and 0.4 L for women) of FEV_1 distribution; FEV_1 z-score = FEV_1 z-score based on the Global Lung Function Initiative 2012 equation; GOLD = Global Initiative for Chronic Obstructive Lung Disease; $ppFEV_1$ = percentage-predicted FEV_1 based on the Global Lung Function Initiative 2012 equation.

cutoffs should be further investigated in a large multiethnic population with a wide age range. In a clinical setting, information such as age, sex, and height of patients with COPD is easily available. Therefore, using FEV_1Q (or other expressions of FEV_1 that are independent of reference equations) for risk classification of patients with COPD might be easy to apply and avoid variation due to dependence on reference equations (5). Furthermore,

multidimensional prognostic indices that combine reference independent FEV_1 expressions with symptoms, exacerbations, risk factors, and/or biomarkers should be investigated further.

This study also had certain limitations. Our methods may not capture nonlinear associations between FEV_1 expressions and mortality (26) or hospitalization, and further studies investigating these approaches are needed.




Figure 2. The areas under the receiver operating characteristic curves (AUCs) for different expressions of FEV₁ and their respective methods of classification of chronic obstructive pulmonary disease (COPD) severity for all-cause mortality ($n = 146$), respiratory mortality ($n = 30$), cardiovascular mortality ($n = 56$), COPD hospitalization ($n = 172$), and pneumonia hospitalization ($n = 96$) among participants with COPD aged ≥ 40 years in the HUNT2 Study (Trøndelag Health Study 2) (1995–1997) followed for 5 years. #Continuous variables. *Grades/quartiles 3–4 were combined because of zero cases in grade/quartile 4 in Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades, FEV₁ z-score grades, and FEV₁ standardized by square of height in meters (FEV₁ · Ht⁻²) grades. **Grades/quartiles 2–4 were analyzed because of zero cases in grade/quartile 1 of GOLD grades, FEV₁ · Ht⁻² quartiles, FEV₁ · Ht⁻³ quartiles, FEV₁ standardized by sex-specific lowest percentile (0.5 L for men and 0.4 L for women) of FEV₁ distribution (FEV₁Q) quartiles, and FEV₁Q grades. Similar differences in AUCs were observed when grade/quartiles 1–2 were combined for respiratory mortality. *P* value represents the differences between ppFEV₁ vs. FEV₁Q, ppFEV₁ quartiles versus FEV₁Q quartiles, and GOLD grades versus FEV₁Q grades. CI = confidence interval; FEV₁ · Ht⁻³ = FEV₁ standardized by cube of height in meters; FEV₁ z-score = FEV₁ z-score based on the Global Lung Function Initiative 2012 equation; ppFEV₁ = percentage-predicted FEV₁ based on the Global Lung Function Initiative 2012 equation.

In summary, these findings highlight improved prediction of outcomes by the use of FEV₁Q. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Acknowledgment: The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Science, Norwegian University of Science and Technology), Trøndelag County Council, and the Norwegian Institute of Public Health. The Lung Study in HUNT2 was partly funded through a nondemanding grant from AstraZeneca Norway. Data on date of death and hospitalizations were obtained from the Norwegian Cause of Death Registry and The Nord-Trøndelag Hospital Trust, respectively.

Laxmi Bhatta, Ph.D.*
Norwegian University of Science and Technology
Trondheim, Norway

Linda Leivseth, Ph.D.
Northern Norway Regional Health Authority
Tromsø, Norway

Xiao-Mei Mai, M.D., Ph.D.
Norwegian University of Science and Technology
Trondheim, Norway

Anne Hildur Henriksen, M.D., Ph.D.
Norwegian University of Science and Technology
Trondheim, Norway

and
Trondheim University Hospital
Trondheim, Norway

David Carslake, Ph.D.
MRC Integrative Epidemiology Unit at the University of Bristol
Bristol, United Kingdom

Yue Chen, M.D., Ph.D.
University of Ottawa
Ottawa, Ontario, Canada

Pablo Martinez-Camblor, Ph.D.
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Arnulf Langhammer, M.D., Ph.D.†
Norwegian University of Science and Technology
Levanger, Norway

and
Nord-Trøndelag Hospital Trust
Levanger, Norway

Ben Michael Brumpton, Ph.D.†
Norwegian University of Science and Technology
Trondheim, Norway

Trondheim University Hospital
Trondheim, Norway

and
MRC Integrative Epidemiology Unit at the University of Bristol
Bristol, United Kingdom

*Corresponding author (e-mail: laxmi.bhatta@ntnu.no).

†These authors contributed equally to this work.

References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive

- pulmonary disease, 2019 [accessed 2020 Jan 1]. Available from: <https://goldcopd.org/>.
2. Frago CA, Concato J, McAvay G, Yaggi HK, Van Ness PH, Gill TM. Staging the severity of chronic obstructive pulmonary disease in older persons based on spirometric Z-scores. *J Am Geriatr Soc* 2011;59: 1847–1854.
 3. Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. *Eur Respir J* 2014;43:505–512.
 4. Huang TH, Hsiue TR, Lin SH, Liao XM, Su PL, Chen CZ. Comparison of different staging methods for COPD in predicting outcomes. *Eur Respir J* 2018;51:1700577.
 5. Miller MR, Pedersen OF. New concepts for expressing forced expiratory volume in 1 s arising from survival analysis. *Eur Respir J* 2010;35:873–882.
 6. Miller MR, Pedersen OF, Dirksen A. A new staging strategy for chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2007;2:657–663.
 7. Miller MR, Pedersen OF, Lange P, Vestbo J. Improved survival prediction from lung function data in a large population sample. *Respir Med* 2009;103:442–448.
 8. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London. London: Oxford University Press; 1976.
 9. Sorlie PD, Kannel WB, O'Connor G. Mortality associated with respiratory function and symptoms in advanced age: the Framingham Study. *Am Rev Respir Dis* 1989;140:379–384.
 10. Bhatta L, Leivseth L, Mai X-M, Chen Y, Henriksen AH, Langhammer A, et al. Prevalence and trend of COPD from 1995–1997 to 2006–2008: the HUNT study, Norway. *Respir Med* 2018;138:50–56.
 11. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al.; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40:1324–1343.
 12. Standardization of spirometry, 1994 update: American Thoracic Society. *Am J Respir Crit Care Med* 1995;152:1107–1136.
 13. Langhammer A, Johannessen A, Holmen TL, Melbye H, Stanojevic S, Lund MB, et al. Global Lung Function Initiative 2012 reference equations for spirometry in the Norwegian population. *Eur Respir J* 2016;48: 1602–1611.
 14. Hankinson JL, Eschenbacher B, Townsend M, Stocks J, Quanjer PH. Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test. *Eur Respir J* 2015;45: 1283–1292.
 15. Bhatta L, Leivseth L, Mai X-m, Henriksen AH, Carslake D, Chen Y, et al. Spirometric classifications of COPD severity as predictive markers for clinical outcomes: the HUNT Study [preprint]. *medRxiv* 2020 Available from: <https://www.medrxiv.org/content/10.1101/2020.11.03.20221432v1>.
 16. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005;26:948–968.
 17. De'ath G. Multivariate regression trees: a new technique for modeling species-environment relationships. *Ecology* 2002;83:1105–1117.
 18. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. *Biometrics* 2005;61:92–105.
 19. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. *BMC Med Res Methodol* 2017;17:53.
 20. Saha P, Heagerty PJ. Time-dependent predictive accuracy in the presence of competing risks. *Biometrics* 2010;66: 999–1011.
 21. Martínez-Cambor P, Pardo-Fernández JC. Smooth time-dependent receiver operating characteristic curve estimators. *Stat Methods Med Res* 2018;27:651–674.
 22. Bansal A, Heagerty PJ. A tutorial on evaluating the time-varying discrimination accuracy of survival models used in dynamic decision making. *Med Decis Making* 2018;38:904–916.
 23. Martínez-Cambor P, Corral N. A general bootstrap algorithm for hypothesis testing. *J Stat Plan Inference* 2012;142:589–600.
 24. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag Study. *Eur Respir J* 2001;18: 770–779.
 25. Moreira S, Fernandes M, Silva M, Escalera D, Staats R, Valença J, et al. Comparison of the FEV1 value from five reference equations: ESCS 71|83|93, NHANES and GLI. *Eur Respir J* 2017;50: PA2507.
 26. Tejero E, Prats E, Casitas R, Galera R, Pardo P, Gavilán A, et al. Classification of airflow limitation based on z-score underestimates mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2017;196: 298–305.

Copyright © 2021 by the American Thoracic Society



Preclinical Development of Virulence-attenuated *Streptococcus pneumoniae* Strains Able to Enhance Protective Immunity against Pneumococcal Infection

To the Editor:

The existing vaccination strategies for prevention of adult *Streptococcus pneumoniae* lung infections are only partially effective (1) and novel preventive approaches are required. Recent data have shown that adults develop immunity to *S. pneumoniae* through repeated episodes of asymptomatic nasopharyngeal colonization (2–6). This naturally acquired immunity includes protective responses to both protein and capsular antigens (2–6) and is boosted by recolonization events (4, 7). These data suggest that deliberate nasopharyngeal administration of live *S. pneumoniae* could prevent serious *S. pneumoniae* infections by strengthening preexisting cross-serotype protective immunity that inhibits nasopharyngeal colonization with virulent strains, increases antigen-specific systemic immunity, and perhaps strengthens alveolar macrophage-mediated innate immunity (2, 3, 6, 7). This strategy would require *S. pneumoniae* strains able to stimulate protective immunity but unable to cause disease in a population with an underlying increased susceptibility to

E.R.-S. and G.E. are supported by Medical Research Council grants R/N02687X/1 and MR/R001871/1, respectively. This work was undertaken at University College London Hospitals/University College London, who received a proportion of funding from the Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centre's funding scheme. R.S.H. is supported through the NIHR Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government, and D.G. receives support from the NIHR Great Ormond Street Institute of Child Health Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Author Contributions: E.R.-S. contributed to conceiving, designing, conducting, and analyzing experiments; designing the study; and writing the manuscript. E.R.-S., G.E., P.F., R.R.d.A., and R.N. contributed to conducting and analyzing experiments. R.S.H., S.B.G., D.M.F., and J.S.B. contributed to conceiving and designing the study. E.R.-S., P.F., D.G., and R.S.H. contributed to designing and analyzing experiments. J.S.B. contributed to designing and analyzing experiments and writing the manuscript. All authors have read and approved the manuscript.

Originally Published in Press as DOI: 10.1164/rccm.202011-4161LE on December 17, 2020